Trelstar is a drug owned by Verity Pharmaceuticals Inc. It is protected by 2 US drug patents filed from 2013 to 2019. Out of these, 1 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 30, 2029. Details of Trelstar's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10166181 | Slow release pharmaceutical composition made of microgranules |
Jun, 2029
(4 years from now) | Active |
| US5776885 | Sustained and controlled release of water insoluble polypeptides |
Jul, 2015
(9 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Trelstar's patents.
Latest Legal Activities on Trelstar's Patents
Given below is the list of recent legal activities going on the following patents of Trelstar.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 Jul, 2022 | US10166181 |
| Post Issue Communication - Certificate of Correction | 08 Jan, 2020 | US10166181 |
| Email Notification Critical | 27 Sep, 2019 | US10166181 |
| Mail-Petition Decision - Dismissed Critical | 24 Sep, 2019 | US10166181 |
| Petition Decision - Dismissed Critical | 23 Sep, 2019 | US10166181 |
| Email Notification Critical | 06 Mar, 2019 | US10166181 |
| Change in Power of Attorney (May Include Associate POA) Critical | 06 Mar, 2019 | US10166181 |
| Petition Entered | 25 Feb, 2019 | US10166181 |
| Patent Issue Date Used in PTA Calculation Critical | 01 Jan, 2019 | US10166181 |
| Recordation of Patent Grant Mailed Critical | 01 Jan, 2019 | US10166181 |
FDA has granted several exclusivities to Trelstar. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Trelstar, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Trelstar.
Exclusivity Information
Trelstar holds 1 exclusivities. All of its exclusivities have expired in 2013. Details of Trelstar's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 10, 2013 |
Several oppositions have been filed on Trelstar's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Trelstar's generic, the next section provides detailed information on ongoing and past EP oppositions related to Trelstar patents.
Trelstar's Oppositions Filed in EPO
Trelstar has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 13, 2017, by Generics (Uk) Ltd. This opposition was filed on patent number EP08763237A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP12172232A | Apr, 2019 | Generics [UK] Ltd | Granted and Under Opposition |
| EP08763237A | Sep, 2017 | Ferring B.V. | Revoked |
| EP08763237A | Sep, 2017 | Generics (UK) Ltd | Revoked |
US patents provide insights into the exclusivity only within the United States, but Trelstar is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Trelstar's family patents as well as insights into ongoing legal events on those patents.
Trelstar's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Trelstar's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 30, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Trelstar Generics:
There are no approved generic versions for Trelstar as of now.
Alternative Brands for Trelstar
There are several other brand drugs using the same active ingredient (Triptorelin Pamoate) as Trelstar. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Azurity |
|
About Trelstar
Trelstar is a drug owned by Verity Pharmaceuticals Inc. Trelstar uses Triptorelin Pamoate as an active ingredient. Trelstar was launched by Verity in 2010.
Approval Date:
Trelstar was approved by FDA for market use on 10 March, 2010.
Active Ingredient:
Trelstar uses Triptorelin Pamoate as the active ingredient. Check out other Drugs and Companies using Triptorelin Pamoate ingredient
Dosage:
Trelstar is available in injectable form for intramuscular use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 22.5MG BASE/VIAL | INJECTABLE | Prescription | INTRAMUSCULAR |
| EQ 11.25MG BASE/VIAL | INJECTABLE | Prescription | INTRAMUSCULAR |
| EQ 3.75MG BASE/VIAL | INJECTABLE | Prescription | INTRAMUSCULAR |